DaVita (DVA) Projected to Post Quarterly Earnings on Monday

DaVita (NYSE:DVA) will likely be issuing its Q4 2025 results after the market closes on Monday, February 2nd. Analysts expect the company to announce earnings of $3.34 per share and revenue of $3.5061 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 2, 2026 at 5:00 PM ET.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.59 EPS. On average, analysts expect DaVita to post $11 EPS for the current fiscal year and $13 EPS for the next fiscal year.

DaVita Stock Up 1.8%

Shares of NYSE DVA opened at $109.21 on Friday. DaVita has a 52 week low of $101.00 and a 52 week high of $179.60. The firm has a market cap of $7.71 billion, a P/E ratio of 11.25, a P/E/G ratio of 0.66 and a beta of 0.99. The business’s 50 day moving average price is $113.59 and its 200 day moving average price is $125.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DVA. Canada Pension Plan Investment Board acquired a new stake in DaVita in the 2nd quarter valued at $43,000. iSAM Funds UK Ltd purchased a new position in DaVita during the third quarter valued at $46,000. NewEdge Advisors LLC grew its position in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the period. Advisory Services Network LLC purchased a new stake in shares of DaVita during the third quarter worth about $115,000. Finally, Kestra Private Wealth Services LLC acquired a new position in shares of DaVita during the 3rd quarter worth about $203,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DVA. Truist Financial cut their price objective on shares of DaVita from $140.00 to $128.00 and set a “hold” rating on the stock in a research note on Monday, January 5th. Barclays cut their price target on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 30th. UBS Group reiterated a “buy” rating on shares of DaVita in a research note on Monday, December 15th. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and an average price target of $145.60.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.